Should rare complications of treatment influence decision-making in ulcerative colitis? [1]

Inflammatory Bowel Diseases

Volumn 13, Issue 2, 2007, Pages 242-

  Siegel, Corey A ^a   Bensen, Steve P ^a   Ely, Pamela ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIMETABOLITE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INFLIXIMAB; MERCAPTOPURINE; PREDNISONE; VALACICLOVIR;

ADULT; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DECISION MAKING; HEMOPHAGOCYTIC SYNDROME; HUMAN; HUMAN TISSUE; INFECTION; INFORMED CONSENT; LABORATORY TEST; LETTER; MALE; PANCYTOPENIA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; ULCERATIVE COLITIS;

ADULT; COLITIS, ULCERATIVE; FATAL OUTCOME; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; OPPORTUNISTIC INFECTIONS;

EID: 34249335295     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20064     Document Type: Letter

References (2)

1. James D, Stone C, Wang H, et al. Reactive hemophagocytic syndrome complicating the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:573-580.
2. Siegel C, Olenec C, Wartman D, et al. Hemophagocytic syndrome: a complication of ulcerative colitis or side-effect of 6-MP therapy? Am J Gastroenterol. 2004;99:S134.